-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form...
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal...
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
Reached a long-term business cooperation with a large pharmaceutical company to help it promote production licensing and commercial supervision and app...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
-Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasir...
Demonstrates competitiveness of hyaluronidase-based ADC SC conversion platform Confirms stability of high-concentration ADC SC formulations and improv...
-Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin Am...
SCIEX, a Danaher company and leader in life science analytical technologies, announced new solutions designed to help clinical laboratories move from sam...
“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellen...
Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced that the UK Medicines and Healthcare ...
FDA supports advancement of IVMED-85 into Phase 2 clinical development for pediatric myopia and provides alignment on key elements of the develop...
ArisGlobal brings a mission-critical, AI-native platform spanning regulatory, safety, quality and medical affairs that serves as a single sourc...
The recent Bundibugyo Ebola virus outbreak underscored the limitations of relying solely on highly targeted diagnostics, highlighting the need for more ada...
© 2026 Biopharma Boardroom. All Rights Reserved.
